Lava, smoldering from dropping lead asset, lays off 30% of staff to save cash
With Lava Therapeutics still smoldering from the decision to dump its lead blood cancer drug, the biotech is now laying off 30% of its staff in an effort to conserve cash.
With Lava Therapeutics still smoldering from the decision to dump its lead blood cancer drug, the biotech is now laying off 30% of its staff in an effort to conserve cash.
